Difference between revisions of "WSI21-129"

From MGH Learn Pathology
(Edited automatically from page learn:wsidashboard.)
 
(94 intermediate revisions by 11 users not shown)
Line 1: Line 1:
−
{{dziOrderStudySet
+
{{ServiceRequest
−
|order_date=July 06, 2021 12:54:16 PM
+
|intent=order
−
|user=Em99
+
|category=409073007
−
|class_name=Study Set
+
|priority=routine
−
|status=Created
+
|code=study
−
|collection_name=Cytopathology
+
|orderDetail=order
−
|class_type=Cytology
+
|authoredOn=July 06, 2021 12:54:16 PM
−
|collection_topic=Thyroid
+
|requester=Em99
−
|requested_by=IAC
+
|locationCode=learn
−
|restrict_access=Public
+
|access=public
 +
|subject=MGH
 +
|performer=MGH
 +
|supportingInfo=Cytology
 +
|requisition=Cytology
 +
|reasonCode=Thyroid
 +
}}
 +
{{status
 +
|status=completed
 +
|identifier=WSI21-129
 +
|requester=Si787
 +
|authoredOn=March 10, 2022 10:38:16 AM
 +
}}
 +
{{status
 +
|status=active
 +
|identifier=WSI21-129
 +
|requester=Iac0
 +
|authoredOn=May 31, 2022 17:49:07
 +
}}
 +
{{status
 +
|status=submitted
 +
|identifier=WSI21-129
 +
|requester=Iac0
 +
|authoredOn=May 31, 2022 17:51:17
 +
}}
 +
{{status
 +
|status=received
 +
|identifier=WSI21-129
 +
|requester=Aja51
 +
|authoredOn=Jun 10, 2022 19:40:55
 +
}}
 +
{{status
 +
|status=scanning
 +
|identifier=WSI21-129
 +
|requester=Aja51
 +
|authoredOn=Jun 20, 2022 13:56:31
 +
}}
 +
{{status
 +
|status=completed
 +
|identifier=WSI21-129
 +
|requester=Aja51
 +
|authoredOn=Jun 20, 2022 13:57:59
 +
}}
 +
{{status
 +
|status=active
 +
|identifier=WSI21-129
 +
|requester=Iac0
 +
|authoredOn=Jul 22, 2022 19:45:11
 +
}}
 +
{{status
 +
|status=submitted
 +
|identifier=WSI21-129
 +
|requester=Iac0
 +
|authoredOn=Jul 22, 2022 19:45:58
 +
}}
 +
{{status
 +
|status=received
 +
|identifier=WSI21-129
 +
|requester=Tag62
 +
|authoredOn=Jul 28, 2022 18:32:14
 +
}}
 +
{{status
 +
|status=scanning
 +
|identifier=WSI21-129
 +
|requester=Tag62
 +
|authoredOn=Jul 28, 2022 18:32:22
 +
}}
 +
{{status
 +
|status=completed
 +
|identifier=WSI21-129
 +
|requester=Tag62
 +
|authoredOn=Jul 28, 2022 18:51:50
 +
}}
 +
{{status
 +
|status=active
 +
|identifier=WSI21-129
 +
|requester=Cfh13
 +
|authoredOn=Aug 10, 2022 20:47:41
 +
}}
 +
{{status
 +
|status=submitted
 +
|identifier=WSI21-129
 +
|requester=Aja51
 +
|authoredOn=Aug 11, 2022 13:40:27
 +
}}
 +
{{status
 +
|status=received
 +
|identifier=WSI21-129
 +
|requester=Aja51
 +
|authoredOn=Aug 11, 2022 13:45:29
 +
}}
 +
{{status
 +
|status=scanning
 +
|identifier=WSI21-129
 +
|requester=Aja51
 +
|authoredOn=Aug 12, 2022 12:46:35
 +
}}
 +
{{status
 +
|status=completed
 +
|identifier=WSI21-129
 +
|requester=Aja51
 +
|authoredOn=Aug 12, 2022 20:12:43
 +
}}
 +
{{status
 +
|status=active
 +
|identifier=WSI21-129
 +
|requester=Iac0
 +
|authoredOn=Aug 16, 2022 18:35:09
 +
}}
 +
{{status
 +
|status=submitted
 +
|identifier=WSI21-129
 +
|requester=Iac0
 +
|authoredOn=Aug 16, 2022 18:37:34
 +
}}
 +
{{status
 +
|status=received
 +
|identifier=WSI21-129
 +
|requester=Aja51
 +
|authoredOn=Aug 19, 2022 15:11:54
 +
}}
 +
{{status
 +
|status=scanning
 +
|identifier=WSI21-129
 +
|requester=Aja51
 +
|authoredOn=Aug 19, 2022 19:59:11
 +
}}
 +
{{status
 +
|status=completed
 +
|identifier=WSI21-129
 +
|requester=Aja51
 +
|authoredOn=Sep 02, 2022 15:16:44
 +
}}
 +
{{status
 +
|status=active
 +
|identifier=WSI21-129
 +
|requester=Ez278
 +
|authoredOn=Sep 16, 2022 20:38:49
 +
}}
 +
{{status
 +
|status=submitted
 +
|identifier=WSI21-129
 +
|requester=Ez278
 +
|authoredOn=Sep 16, 2022 20:41:25
 +
}}
 +
{{status
 +
|status=received
 +
|identifier=WSI21-129
 +
|requester=Aja51
 +
|authoredOn=Sep 19, 2022 14:06:37
 +
}}
 +
{{status
 +
|status=scanning
 +
|identifier=WSI21-129
 +
|requester=Aja51
 +
|authoredOn=Sep 19, 2022 18:25:55
 +
}}
 +
{{status
 +
|status=active
 +
|identifier=WSI21-129
 +
|requester=Cfh13
 +
|authoredOn=Sep 19, 2022 20:11:19
 +
}}
 +
{{status
 +
|status=submitted
 +
|identifier=WSI21-129
 +
|requester=Cfh13
 +
|authoredOn=Sep 19, 2022 20:13:30
 +
}}
 +
{{status
 +
|status=received
 +
|identifier=WSI21-129
 +
|requester=Aja51
 +
|authoredOn=Sep 20, 2022 14:34:49
 +
}}
 +
{{status
 +
|status=scanning
 +
|identifier=WSI21-129
 +
|requester=Aja51
 +
|authoredOn=Sep 20, 2022 14:47:43
 +
}}
 +
{{status
 +
|status=active
 +
|identifier=WSI21-129
 +
|requester=Cfh13
 +
|authoredOn=Sep 21, 2022 13:57:30
 +
}}
 +
{{status
 +
|status=submitted
 +
|identifier=WSI21-129
 +
|requester=Cfh13
 +
|authoredOn=Sep 21, 2022 13:59:23
 +
}}
 +
{{status
 +
|status=received
 +
|identifier=WSI21-129
 +
|requester=Aja51
 +
|authoredOn=Sep 22, 2022 12:33:53
 +
}}
 +
{{status
 +
|status=scanning
 +
|identifier=WSI21-129
 +
|requester=Aja51
 +
|authoredOn=Sep 22, 2022 20:28:55
 +
}}
 +
{{status
 +
|status=completed
 +
|identifier=WSI21-129
 +
|requester=Aja51
 +
|authoredOn=Sep 26, 2022 14:16:25
 +
}}
 +
{{status
 +
|status=active
 +
|identifier=WSI21-129
 +
|requester=Lcm51
 +
|authoredOn=Sep 26, 2022 18:17:48
 +
}}
 +
{{status
 +
|status=submitted
 +
|identifier=WSI21-129
 +
|requester=Lcm51
 +
|authoredOn=Sep 26, 2022 18:19:54
 +
}}
 +
{{status
 +
|status=received
 +
|identifier=WSI21-129
 +
|requester=Aja51
 +
|authoredOn=Sep 27, 2022 12:30:07
 +
}}
 +
{{status
 +
|status=scanning
 +
|identifier=WSI21-129
 +
|requester=Aja51
 +
|authoredOn=Sep 27, 2022 14:35:19
 +
}}
 +
{{status
 +
|status=completed
 +
|identifier=WSI21-129
 +
|requester=Aja51
 +
|authoredOn=Oct 07, 2022 14:43:44
 
}}
 
}}
 
{{status
 
{{status
−
|requester=Em99
+
|status=active
−
|authoredOn=July 06, 2021 01:07:16 PM
+
|identifier=WSI21-129
−
|status=Created
+
|requester=Iac0
 +
|authoredOn=Nov 11, 2022 17:58:18
 +
}}
 +
{{status
 +
|status=submitted
 +
|identifier=WSI21-129
 +
|requester=Iac0
 +
|authoredOn=Nov 11, 2022 18:00:42
 +
}}
 +
{{status
 +
|status=active
 +
|identifier=WSI21-129
 +
|requester=Cfh13
 +
|authoredOn=Nov 11, 2022 21:03:07
 +
}}
 +
{{status
 +
|status=submitted
 +
|identifier=WSI21-129
 +
|requester=Cfh13
 +
|authoredOn=Nov 11, 2022 21:13:32
 +
}}
 +
{{status
 +
|status=received
 +
|identifier=WSI21-129
 +
|requester=Aja51
 +
|authoredOn=Nov 15, 2022 15:17:41
 +
}}
 +
{{status
 +
|status=scanning
 +
|identifier=WSI21-129
 +
|requester=Aja51
 +
|authoredOn=Nov 25, 2022 15:42:52
 +
}}
 +
{{status
 +
|status=completed
 +
|identifier=WSI21-129
 +
|requester=Aja51
 +
|authoredOn=Nov 25, 2022 15:50:22
 +
}}
 +
{{status
 +
|status=active
 +
|identifier=WSI21-129
 +
|requester=Ndk6
 +
|authoredOn=Feb 03, 2023 20:02:00
 +
}}
 +
{{status
 +
|status=submitted
 +
|identifier=WSI21-129
 +
|requester=Cfh13
 +
|authoredOn=Feb 13, 2023 14:26:50
 +
}}
 +
{{status
 +
|status=received
 +
|identifier=WSI21-129
 +
|requester=Aja51
 +
|authoredOn=Feb 13, 2023 17:34:11
 +
}}
 +
{{status
 +
|status=scanning
 +
|identifier=WSI21-129
 +
|requester=Aja51
 +
|authoredOn=Feb 17, 2023 19:03:20
 +
}}
 +
{{status
 +
|status=completed
 +
|identifier=WSI21-129
 +
|requester=Aja51
 +
|authoredOn=Feb 17, 2023 19:27:44
 +
}}
 +
{{status
 +
|status=active
 +
|identifier=WSI21-129
 +
|requester=Ndk6
 +
|authoredOn=Feb 17, 2023 22:49:38
 +
}}
 +
{{status
 +
|status=submitted
 +
|identifier=WSI21-129
 +
|requester=Aja51
 +
|authoredOn=Feb 27, 2023 15:38:07
 +
}}
 +
{{status
 +
|status=received
 +
|identifier=WSI21-129
 +
|requester=Aja51
 +
|authoredOn=Mar 03, 2023 14:31:00
 +
}}
 +
{{status
 +
|status=scanning
 +
|identifier=WSI21-129
 +
|requester=Aja51
 +
|authoredOn=Mar 03, 2023 14:35:02
 +
}}
 +
{{status
 +
|status=completed
 +
|identifier=WSI21-129
 +
|requester=Aja51
 +
|authoredOn=Mar 03, 2023 14:45:30
 +
}}
 +
{{status
 +
|status=active
 +
|identifier=WSI21-129
 +
|requester=Cfh13
 +
|authoredOn=Mar 23, 2023 16:32:20
 +
}}
 +
{{status
 +
|status=submitted
 +
|identifier=WSI21-129
 +
|requester=Cfh13
 +
|authoredOn=Mar 23, 2023 16:34:05
 +
}}
 +
{{status
 +
|status=received
 +
|identifier=WSI21-129
 +
|requester=Aja51
 +
|authoredOn=Mar 28, 2023 12:59:08
 +
}}
 +
{{status
 +
|status=scanning
 +
|identifier=WSI21-129
 +
|requester=Aja51
 +
|authoredOn=Mar 28, 2023 12:59:54
 +
}}
 +
{{status
 +
|status=scanning
 +
|identifier=WSI21-129
 +
|requester=Aja51
 +
|authoredOn=Mar 28, 2023 13:00:59
 +
}}
 +
{{status
 +
|status=completed
 +
|identifier=WSI21-129
 +
|requester=Aja51
 +
|authoredOn=Apr 06, 2023 18:18:03
 +
}}
 +
{{status
 +
|status=active
 +
|identifier=WSI21-129
 +
|requester=Mlz8
 +
|authoredOn=Apr 11, 2023 16:47:33
 +
}}
 +
{{status
 +
|status=submitted
 +
|identifier=WSI21-129
 +
|requester=Mlz8
 +
|authoredOn=Apr 11, 2023 16:50:40
 +
}}
 +
{{status
 +
|status=received
 +
|identifier=WSI21-129
 +
|requester=Aja51
 +
|authoredOn=May 01, 2023 18:51:11
 +
}}
 +
{{status
 +
|status=scanning
 +
|identifier=WSI21-129
 +
|requester=Aja51
 +
|authoredOn=May 01, 2023 18:53:59
 +
}}
 +
{{status
 +
|status=completed
 +
|identifier=WSI21-129
 +
|requester=Aja51
 +
|authoredOn=May 01, 2023 19:02:03
 +
}}
 +
{{status
 +
|status=completed
 +
|identifier=WSI21-129
 +
|requester=Aja51
 +
|authoredOn=May 01, 2023 18:55:04
 +
}}
 +
{{status
 +
|status=active
 +
|identifier=WSI21-129
 +
|requester=Mlz8
 +
|authoredOn=May 19, 2023 19:15:43
 +
}}
 +
{{status
 +
|status=submitted
 +
|identifier=WSI21-129
 +
|requester=Mlz8
 +
|authoredOn=May 19, 2023 19:18:33
 +
}}
 +
{{status
 +
|status=received
 +
|identifier=WSI21-129
 +
|requester=Aja51
 +
|authoredOn=May 26, 2023 17:41:52
 +
}}
 +
{{status
 +
|status=scanning
 +
|identifier=WSI21-129
 +
|requester=Aja51
 +
|authoredOn=Jun 01, 2023 14:41:46
 +
}}
 +
{{status
 +
|status=completed
 +
|identifier=WSI21-129
 +
|requester=Aja51
 +
|authoredOn=Jun 01, 2023 14:55:03
 
}}
 
}}

Latest revision as of 09:56, June 1, 2023


Request type Study
Subspecialty Cytology
Set Cytology
Topic Thyroid
Presenter MGH


Toggle columns: Diagnosis

Case Clinical history Requester Diagnosis
Case Clinical history Requester Diagnosis

Case 1


51M small nodule on US. Iac0 Medullary thyroid carcinoma

Case 2


92F with large left thyroid nodule Mlz8 Suspicious for Hurthle cell neoplasm

Case 3


57 year-old male. Nodule inferior to thyroid. Iac0 Parathyroid tissue.

Case 4


76yo female with thyroid nodules Mlz8 Hashimoto thyroiditis (part A); Papillary thyroid carcinoma arising in Hashimoto thyroiditis (part B)

Case 5


66 year old woman with a 1.6 cm thyroid nodule Lz17 Hurthle cell neoplasm (note: serum calcitonin levels undetectable)

Case 6


46yo female with right thyroid nodule Mlz8 Medullary thyroid carcinoma

Case 7


16M. Thyroid nodule. Iac0 AUS. Thyroid follicular cells with macrofollicular architecture and focal nuclear atypia. Thyroseq with DICER1 mutation.

Case 8


70M. Thyroid mass. Iac0 Anaplastic thyroid carcinoma.

Case 9


29 year old F with a 2 cm thyroid nodule. Cfh13 Positive for malignant cells: Papillary thyroid carcinoma.

Case 10


48F. History of thyroid carcinoma. New lung mass. Iac0 Metastatic thyroid follicular carcinoma with oncocytic (Hurthle cell) features.

Case 11


77yo woman with 3.3cm right thyroid nodule Ez278 Medullary thyroid carcinoma

Case 12


75 yo F with multi-nodular goiter. Largest nodule 2 cm. Cfh13 Suspicious for Hurthle Cell neoplasm (Bethesda Category IV)

Case 13


78 yo F with longstanding thyroid nodule with a recent rapid increase in size. Cfh13 Positive for anaplastic thyroid carcinoma.

Case 14


73 year old F with prior thyroidectomy and current flank mass sampled in the FNA clinic. Lcm51 Metastatic follicular thyroid carcinoma with high grade features.

Case 15


72F. 2.7 cm thyroid mass. Iac0 Medullary thyroid carcinoma.

Case 16


70 yo F with a new 2 cm thyroid nodule. Cfh13 Initial sign-out: Positive for malignant cells. Papillary carcinoma. Subsequent surgical specimen: Tubular adenoma.

Case 17


78 yo F with a growing thyroid nodule. Cfh13 Suspicious for a Hurthle cell (oncocytic) neoplasm (Bethesda Category IV). Thyroseq: Negative.

Case 18


26 yo F with an incidental thyroid nodule Cfh13 Suspicious for a follicular neoplasm (Bethesda category IV). Cellular microfollicular lesion • suspicious for a follicular neoplasm.

Case 19


45 yo female with 8 mm nodule Ndk6 Papillary thyroid carcinoma • follicular variant

Case 20


40ish year old woman with history of thyroid tumor. Tlh39 Metastatic medullary thyroid carcinoma.

Case 21


76 up man with a thyroid nodule Cfh13 Papillary carcinoma with abundant cystic degeneration

Case 22


34F • right thyroid nodule Mlz8 Suspicious for Hurthle cell neoplasm

Case 23


24F • left neck mass Mlz8 Papillary thyroid carcinoma

Case 24


51 yo female Dc679 PTC in background of HASH

Case 25


41 yo female Dc679 Hashimoto thyroiditis

Case 26


47 yo male Dc679 Medullary Thyroid carcinoma

Case 27


57 yo female Dc679 Papillary Thyroid Carcinoma

Case 28


44 years old woman with thyroid nodule Lt511 granulomatous thyroiditis

Case 29


57F • thyroid nodule. Iac0 Follicular neoplasm • oncocytic type.

Case 30


73 yo male • right neck Ndk6 Metastatic papillary thyroid carcinoma

Case 31


35 yo female • 24 mm thyroid nodule Ndk6 Malignant cells present • cytomorphologically suggestive of cystic variant of papillary thyroid carcinoma

Case 32


52 yo female • mid/lower pole nodule • solid • very hypoechoic • irregular borders- 10mm Ndk6 Papillary thyroid carcinoma

Case 33


37 yo female • treated thyroid cancer; FDG+ mass Ndk6 Neuroendocrine tumor consistent with recurrence of the patient’s known neuroendocrine carcinoma

Case 34


53 yo male • left thyroid nodule • solid • heterogeneous with coarse calcifications; 28mm Ndk6 Oncocytic neoplasm with widespread nuclear atypia • favor oncocytic papillary thyroid carcinoma

Case 35


66 yo M w/ 20 mm thyroid nodule Ndk6 Papillary thyroid carcinoma

Case 36


47 yo F w/ thyroid nodule Ndk6 Papillary thyroid carcinoma







































Retrieved from "https://learn.mghpathology.org/index.php?title=WSI21-129&oldid=109877"
  • Powered by MediaWiki
  • Search Powered by Cargo
  • Massachusetts General Hospital